Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Recruiting now · Not applicable

Conditions studied: PONV, Cerebellopontine Angle Tumor, Microvascular Decompression Surgery, Postoperative Analgesia

In brief

This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus/defecation, and gastrointestinal function scores.

Key facts

Study ID
NCT07479446
Run by
Xuanwu Hospital, Beijing
People needed
174
Starts
2026-03-25
Expected to finish
2027-09-30
Last updated by the study team
2026-05-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.